IgE and TGF-β Signaling: From Immune to Cardiac Remodeling

IgE and TGF-β Signaling: From Immune to Cardiac Remodeling

Hua Cao,1 Chungang Xiao,1 Zhangxiu He,2 Hong Huang,3,4 Huifang Tang1,4 1The First Affiliated Hospital, Department of Cardiology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of China; 2The First Affiliated Hospital, Department of Nephrology, Hengyang...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cao H, Xiao C, He Z, Huang H, Tang H
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
cardiac remodeling
ige- fcεr1
immunoglobulins
tgf-β
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/11b3b56f2cfb49bea872c1e7c6b57c67
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:11b3b56f2cfb49bea872c1e7c6b57c67
record_format dspace
spelling oai:doaj.org-article:11b3b56f2cfb49bea872c1e7c6b57c672021-12-02T17:47:55ZIgE and TGF-β Signaling: From Immune to Cardiac Remodeling1178-7031https://doaj.org/article/11b3b56f2cfb49bea872c1e7c6b57c672021-10-01T00:00:00Zhttps://www.dovepress.com/ige-and-tgf--signaling-from-immune-to-cardiac-remodeling-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Hua Cao,1 Chungang Xiao,1 Zhangxiu He,2 Hong Huang,3,4 Huifang Tang1,4 1The First Affiliated Hospital, Department of Cardiology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of China; 2The First Affiliated Hospital, Department of Nephrology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of China; 3The First Affiliated Hospital, Institute of Clinical Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of China; 4The First Affiliated Hospital, Institute of Cardiovascular Disease, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of ChinaCorrespondence: Hong Huang; Huifang TangThe First Affiliated Hospital, Institute of Cardiovascular Disease, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of ChinaEmail trave1@126.com; tanghuifang999@163.comAbstract: Cardiac remodeling is accompanied by cardiac hypertrophy, fibrosis, and dysfunction, eventually leading to heart failure (HF). However, the molecular mechanisms involved in cardiac remodeling are complicated, especially the association with immune. Immunoglobulin E (IgE) is a class of immunoglobulins involved in immune response to specific allergens. Recently, Zhao et al characterized a novel specific role of IgE and its high affinity receptor (FcϵR1) in directly promoting pathological myocardial remodeling and cardiac dysfunction. Additionally, upon blocking IgE-FcϵR1 signaling using FcϵR1 genetic depletion or by administrating the anti-IgE monoclonal antibody omalizumab (Oma) in mice, they observed that cardiac hypertrophy and cardiac interstitial fibrosis induced by angiotensin II (Ang II) or transverse aortic constriction (TAC) were significantly suppressed. In contrast, IgE administration alone can aggravate pathological cardiac remodeling and dysfunction. RNA-seq and downstream analysis indicated that TGF-β was the common pathway and the most pivotal mediator in IgE-FcϵR1-induced cardiac remodeling and dysfunction. Furthermore, the administration of a TGF-β inhibitor could ameliorate cardiac remodeling and improve cardiac function. Therefore, these findings suggest that IgE-FcϵR1 maybe promising therapeutic targets for cardiac remodeling and provide an experimental basis for the use of omalizumab for HF patients combined with high serum IgE levels or allergic diseases.Keywords: cardiac remodeling, IgE- FcϵR1, immunoglobulins, TGF-&#x03B2Cao HXiao CHe ZHuang HTang HDove Medical Pressarticlecardiac remodelingige- fcεr1immunoglobulinstgf-βPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 5523-5526 (2021)
institution DOAJ
collection DOAJ
language EN
topic cardiac remodeling
ige- fcεr1
immunoglobulins
tgf-β
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
spellingShingle cardiac remodeling
ige- fcεr1
immunoglobulins
tgf-β
Pathology
RB1-214
Therapeutics. Pharmacology
RM1-950
Cao H
Xiao C
He Z
Huang H
Tang H
IgE and TGF-β Signaling: From Immune to Cardiac Remodeling
description Hua Cao,1 Chungang Xiao,1 Zhangxiu He,2 Hong Huang,3,4 Huifang Tang1,4 1The First Affiliated Hospital, Department of Cardiology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of China; 2The First Affiliated Hospital, Department of Nephrology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of China; 3The First Affiliated Hospital, Institute of Clinical Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of China; 4The First Affiliated Hospital, Institute of Cardiovascular Disease, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of ChinaCorrespondence: Hong Huang; Huifang TangThe First Affiliated Hospital, Institute of Cardiovascular Disease, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, People’s Republic of ChinaEmail trave1@126.com; tanghuifang999@163.comAbstract: Cardiac remodeling is accompanied by cardiac hypertrophy, fibrosis, and dysfunction, eventually leading to heart failure (HF). However, the molecular mechanisms involved in cardiac remodeling are complicated, especially the association with immune. Immunoglobulin E (IgE) is a class of immunoglobulins involved in immune response to specific allergens. Recently, Zhao et al characterized a novel specific role of IgE and its high affinity receptor (FcϵR1) in directly promoting pathological myocardial remodeling and cardiac dysfunction. Additionally, upon blocking IgE-FcϵR1 signaling using FcϵR1 genetic depletion or by administrating the anti-IgE monoclonal antibody omalizumab (Oma) in mice, they observed that cardiac hypertrophy and cardiac interstitial fibrosis induced by angiotensin II (Ang II) or transverse aortic constriction (TAC) were significantly suppressed. In contrast, IgE administration alone can aggravate pathological cardiac remodeling and dysfunction. RNA-seq and downstream analysis indicated that TGF-β was the common pathway and the most pivotal mediator in IgE-FcϵR1-induced cardiac remodeling and dysfunction. Furthermore, the administration of a TGF-β inhibitor could ameliorate cardiac remodeling and improve cardiac function. Therefore, these findings suggest that IgE-FcϵR1 maybe promising therapeutic targets for cardiac remodeling and provide an experimental basis for the use of omalizumab for HF patients combined with high serum IgE levels or allergic diseases.Keywords: cardiac remodeling, IgE- FcϵR1, immunoglobulins, TGF-&#x03B2
format article
author Cao H
Xiao C
He Z
Huang H
Tang H
author_facet Cao H
Xiao C
He Z
Huang H
Tang H
author_sort Cao H
title IgE and TGF-β Signaling: From Immune to Cardiac Remodeling
title_short IgE and TGF-β Signaling: From Immune to Cardiac Remodeling
title_full IgE and TGF-β Signaling: From Immune to Cardiac Remodeling
title_fullStr IgE and TGF-β Signaling: From Immune to Cardiac Remodeling
title_full_unstemmed IgE and TGF-β Signaling: From Immune to Cardiac Remodeling
title_sort ige and tgf-β signaling: from immune to cardiac remodeling
publisher Dove Medical Press
publishDate 2021
url https://doaj.org/article/11b3b56f2cfb49bea872c1e7c6b57c67
work_keys_str_mv AT caoh igeandtgfbetasignalingfromimmunetocardiacremodeling
AT xiaoc igeandtgfbetasignalingfromimmunetocardiacremodeling
AT hez igeandtgfbetasignalingfromimmunetocardiacremodeling
AT huangh igeandtgfbetasignalingfromimmunetocardiacremodeling
AT tangh igeandtgfbetasignalingfromimmunetocardiacremodeling
_version_ 1718379450385563648

Ejemplares similares